Astrazeneca, the British - Sweden, announcing the AZD7442 drug testing pharmacy does not reach the expected effect on treatment of Covid-19 patients.

In the announcement on June 15, Astrazeneca Pharmaceutic certified AZD7442, the drug combines two single antibodies (MABS), only reaching the level of efficiency of 33% in helping Patients Covid-19 reduce the risk of symptoms

The company acknowledges this level that is negligible in terms of statistically and AZD7442 has failed in the main goal of treating Covid-19 symptoms in patients with infected viruses.

The company is Astrazeneca in Macclesfield, Cheshire, England.

AZD7442 drugs are being tested in the third stage, the final clinical assessment of the safety and performance of Covid-19 disease resistance before the pharmaceutical company asks for licensing countries.

The three-stage testing program was conducted by Astrazeneca on 1,121 volunteers in adulthood, unprecedented Vaccine Covid-19 and was close to NCOV positive.

Although not achieving the results as expected, Astrazeneca will continue to test AZD7442 to assess the ability to use this drug to prevent Covid-19 or treat more serious symptoms.

AZD7442 drug development project is funded by the US government.

AstraZeneca is also a Vaccine Covid-19 pharmaceutical company being widely provided in the world.

However, many European countries continue to concern about the side effects of Astrazeneca vaccine.